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Abstract
The focus on superb quality and value of medical and surgical care has become a 
cornerstone of modern clinical practice. Within the realm of cardiothoracic sur-
gery, quality is synonymous with technically excellent, safely conducted operative 
procedure followed by an uneventful patient recovery and follow-up. Critical to this 
process of clinical value creation is meticulous attention to all aspects of every step 
along the management continuum. From surgical quality improvement perspective, 
the reduction in blood loss and thus minimization of blood/blood product transfu-
sions are of critical importance. This chapter focuses on the role of biosurgicals as 
useful adjuncts to achieving the ultimate goal of uneventful cardiac procedure and 
thus set the patient’s clinical course for optimal postoperative recovery and long-
term well-being.
Keywords: biosurgical, bleeding, hemostasis, cardiac surgery, transfusions, 
coagulopathy, surgery, complications, coagulation
1. Introduction
A major focus for healthcare providers involved in the management of the 
cardiothoracic surgical patient is not only addressing the primary surgical problem, 
but improving all aspects of the overall care of the patient and providing the best 
value of care. To ensure that value-based aspects of the overall care equation are met 
or exceeded, the management of expenses is inextricable in the context of optimiz-
ing patient outcomes. Specifically, the overall goals of reducing length of stay, 
eliminating infections, minimizing readmissions, and optimizing other clinical out-
comes – especially reducing mortality and perioperative complications – are quickly 
becoming quality indicators that serve as evaluation standards for both surgeons 
and hospitals alike. While there is a trend towards minimizing incisions and the 
invasiveness of surgery with the goal of quickly returning patients back to normal 
daily activities, clearly there must be a balance of safely achieving the primary goals 
of surgery in providing a durable solution to a specific clinical problem. Within the 
ever more complex arena of surgical value-based healthcare, the optimization of 
the utilization of blood and blood products is becoming increasingly important in 
patients undergoing cardiothoracic surgery.
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Overall, each year, surgical procedures in the United States are associated 
with the administration of 15 million units of packed red blood cells (PRBCs) [1]. 
Without a doubt, not only are the absolute number of PRBCs being transfused 
increasing, but once patients receive a transfusion, they are becoming more likely 
to receive multiple units of blood and blood products. The reasons for this are 
complex and often attributed to the complexity of the surgical procedures patients 
are undergoing. But there is also the reality that patients are more likely to be medi-
cated with antiplatelet agents, anticoagulants, and have associated co-morbidities 
that increase their risk for bleeding and bleeding related complications [2]. In addi-
tion, a growing challenge is that there appears to be a decreasing pool of eligible 
donors of blood and blood products. It has been estimated that up to 40–60% of all 
patients who undergo open heart surgery will receive a blood transfusion during 
their index hospitalization, and cardiac surgery is responsible for the consumption 
of 10–15% of the total blood supply in the United States [3]. The significance of 
these numbers cannot be underappreciated, as there is a growing recognition that 
transfusions are associated with worse short and long-term patient outcomes. In 
addition, the use of blood and blood products after cardiac surgery has been associ-
ated with other adverse consequences beyond worse clinical outcomes, includ-
ing increased length of stay, increase risk for early (<30 day) readmission, and 
increased overall costs of care. Furthermore, even for those patients who do not 
receive a transfusion, there are concerns that the development of a post-operative 
anemia – specifically a significant change in baseline hemoglobin from pre- to post-
operative – has also been associated with worse outcomes and a prolongation of the 
recovery period [4].
2. Background
As discussed above, blood transfusions are associated with a variety of potential 
adverse clinical complications [4]. Allergic reactions after transfusions are well 
known and might be associated with other significant immunologic responses such 
as post-operative fevers, which might prompt additional testing, blood draws, and 
potential interventions, the least of which is starting broad-spectrum antibiot-
ics, that might precipitate other expensive, resources-intensive, and occasionally 
dangerous therapies [5]. Transfusion related lung injury (TRALI) can also be 
clinically challenging and can result in prolongation of the need for post-operative 
mechanical ventilation and the complications associated with being on the ventila-
tor beyond brief periods of time. In addition, while infectious complications after 
transfusions are becoming less common with advanced blood banking techniques, 
they do nonetheless occur, and when they do occur, the implications can be sig-
nificant with regards to worse outcomes, increased costs, and increased resource 
utilization. For example, despite advanced blood banking techniques and testing, 
Hepatitis B infections can still occur in 1 out of every 200,000 transfusions, while 
the Human Immunodeficiency Virus (HIV) is believed to be transmitted in about 
1 out of 2 million transfusions. Some estimates suggest that as little as 1–2 units of 
PRBCs transfused after cardiac surgery can result in a twofold increase in overall 
post-operative mortality [6]. Furthermore, it has been reported that each unit of 
PRBCs given is associated with a 27% relative increase in the risk of developing a 
post-operative infection – most commonly, pneumonia [7]. At baseline, a major 
infection after cardiac surgery will develop in 1 out of 20 patients. However, for 
those receiving transfusions, this risk of infection increases to about 1 out of 8 [8].
Additionally, growing evidence suggests that bleeding and transfusions can 
result in a substantial increase in healthcare costs. As mentioned above, but more 
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specifically, significant bleeding has been correlated with an increase in surgical 
site infections, all types of Methicillin-resistant Staphylococcus aureus (MRSA) 
infections, ventilator associated pneumonias, central line associated bloodstream 
infections, and Clostridium difficile infections, all of which significantly increase 
the associated length of stay, need for post-discharge resources, and total health-
care costs [9, 10]. These expenses and complications also need to be considered 
in the context of the risk of developing major morbidity and/or mortality from 
the consequences of acute on chronic organ-system dysfunction (or multi-organ 
failure) associated with any type of coagulopathy, especially when the bleeding 
results in hypotension and organ malperfusion syndromes. Even if not directly 
associated with an identifiable complication, bleeding and the need for transfu-
sions is associated with increased costs associated with the patients remaining in 
the intensive care unit (ICU). Even though prolonged ICU stays are associated with 
increased complications and costs, the simple decision to keep a patient in an ICU 
after cardiac surgery when a bleeding event has occurred (independent of, but 
often associated with the need for blood or blood products) is also associated with a 
substantial increase in hospital costs, increased overall length of stay, less efficient 
bed utilization, and potentially lost opportunity costs. As such, factors and process 
interventions aimed at improving blood and blood product utilization are often a 
major focus of any ICU stay reduction initiatives or justification for developing a 
hospital-wide blood conservation program [11].
As discussed, transfusion rates associated with cardiac surgery have been 
directly linked to overall programmatic quality and costs. Therefore, an objective 
blood conservation program can substantially reduce the cost associated with 
blood and blood product utilization. These concepts are especially important 
with the trend towards fixed payment and bundled payment systems in which 
additional postoperative charges or complications (such as re-explorations or 
readmissions) may not be reimbursed, hence placing the hospital at substantial 
financial risk.
Other issues, such as the burden of retained blood in the chest, while difficult to 
quantify, can result in a variety of negative postoperative problems including:
a. the development of tamponade,
b. low cardiac output,
c. chronic pleural effusions,
d. extended or prolonged monitoring in the intensive care unit,
e. prolonged drainage or monitoring of chest tubes – which can result in 
increased post-operative pain and the need for narcotics,
f. potential delayed in post-operative extubation while monitoring bleeding 
which can result in a variety of issues and complications from prolonged 
mechanical ventilation,
g. mediastinitis,
h. acute pericarditis – with associated/confounding ECG changes and/or 
arrhythmias,
i. long-term development of constrictive pericarditis.
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All of these can have substantial short and long-term adverse implications on 
the patient who is recovering from a major cardiac operation, the least of which 
are the increased risks of all types of infections, as well as other sequelae, such as a 
“trapped lung” from chronic pulmonary consolidation.
3. Blood conservation programs
A key component of reducing blood utilization is the development of a team-
based approach to blood conservation [12]. Simple things such as reducing the 
number of blood draws, trying to convert patients to more elective procedures, and 
reducing the dilutional effects associated with administration of excessive intra-
venous fluid all can contribute significantly to reductions in surgical blood loss. In 
addition, the growing utilization of antiplatelet and anticoagulation agents (some 
of which are irreversible or require expensive antidote reversal agents) in patients 
undergoing cardiac surgery has created a unique set of challenges. Therefore, any 
and all opportunities to discontinue antiplatelet and/or anticoagulation medications 
(unless there are absolute or carefully considered relative contraindications) and 
allow for return of normal platelet and coagulation function prior to cardiac surgery 
have been shown to further reduce blood and blood product utilization after major 
surgical interventions [13]. Other patient factors may contribute to major bleed-
ing complications. Among those factors are baseline low platelet counts, anemia, 
renal failure, liver disease, morbid obesity, routinely administrated prophylaxis for 
deep-vein thrombosis for hospitalized patients (especially if not discontinued in a 
timely manner), as well as the need for emergent procedures and catheterizations. 
The routine use of heparin-based medications in patients with acute coronary 
syndromes or critical coronary lesions has been associated with the consumption 
of key coagulation factors and linked to an increased risk of post-operative coagu-
lopathies. All of these factors have been associated with increased blood utilization 
and transfusion rates. Without a doubt, there must be an emphasis on a team-based 
approach to blood conservation that must focus on a continuous modification and 
improvement in the associated patientcare processes and variables to every extent 
possible [13].
An extremely important point is the recognition that many patients are on some 
type of blood thinning agent. Not only is it imperative that the need, both in the 
short-term as well as the long-term, for such agents be objectively evaluated (espe-
cially since many patients have been on therapies for years for reasons they cannot 
even remember, for indications that might have only required a short course of ther-
apy but there is a reluctance to discontinue, or for reasons for which there might be 
little evidence-based data to support long-term use), but it is just as important that 
all healthcare providers understand the implications of varying doses, bio-avail-
abilities, mechanisms of action, and drug-drug interactions, as well as the potential 
impact of homeopathic medications or herbal supplements, availability and use of 
reversal agents, patient compliance. Additionally, it is important they understand 
the overall impact that either using these medications or potentially withholding 
them prior to surgery may have on surgical bleeding and transfusion rates.
There is also growing evidence that extensive testing of patients during their 
hospitalization may contribute to the development of an iatrogenic or hospital-
acquired anemia and, hence, also lead to an increase in transfusion rates. In one 
study, for a routine hospital admission for cardiac surgery, it has been estimated 
that an average patient receives approximately 115 separate tests. This, in turn, 
translates into almost several hundred milliliters (or 1.5–2 units) of blood drawn 
for diagnostic purposes alone [14]! Minimizing or optimizing these labs may have 
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an inherent benefit in reducing the incidence of iatrogenic-induced anemia that 
subsequently results in transfusions. Furthermore, the development of reason-
able transfusion triggers is also important and should be based upon physiologic 
criteria and subjected to continuous quality improvement initiatives that hold all 
members of the team accountable. Nevertheless, despite the growing evidence 
that demonstrates the potential benefits of a restrictive transfusion policy, it must 
be remembered – and potentially discussed daily in the context of individualized 
patient care – that some patients might benefit from a transfusion [1].
Probably the most important and obvious source of postoperative transfusions 
is the occurrence of surgical bleeding. Steps taken to reduce surgical bleeding are of 
critical importance, and while good surgical technique and avoidance of excessive 
tissue trauma is always important, it is not the sole explanation for why patients 
might bleed after surgery. As discussed previously, there are extensive reasons 
why patients, even with the most meticulous of surgical techniques, experience 
peri-operative bleeding events. Obviously, avoiding preoperative anticoagulants 
and antiplatelet agents is critical, but there are also a variety of intra-operative steps 
that can be taken to reduce the risks for peri-operative bleeding. Such steps include 
pre-bypass retrograde autologous blood priming, intra-operative banking of blood, 
and minimization of bypass times, just to name a few (of which a comprehensive 
discussion of each is beyond the scope of this chapter). In addition, there are a 
variety of biologically active agents that can augment the natural clotting process 
in patients undergoing cardiothoracic surgery [15, 16]. Understanding the biologic 
mechanisms of action, especially in the context of an inherent clotting defect(s) 
within a specific patient may be helpful when dealing with this challenging prob-
lem. A cornerstone to this concept is at least a basic understanding of the clotting 
cascade and the normal hemostatic process with regards to where certain agents 
act to interrupt the body’s normal response to tissue injury and clotting (Figure 1). 
Figure 1. 
Intrinsic, extrinsic and final common pathways of the clotting cascade.
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Intraoperatively, hemostatic agents are typically supplied as pastes, gels, foams, 
powders, glues, sprays, and woven cloths or meshes [17].
Recognizing the individual mechanisms of action, advantages, and limitations 
of each agent is important for their optimal and efficient use. Surveys of surgeons 
have shown that integration of biological agents to control hemostasis can result in a 
substantial reduction in postoperative bleeding [18]. However, similar surveys have 
also demonstrated that, often as a lack of understanding of how each agent works 
and where it interacts within the clotting cascade, the effectiveness of some agents 
is limited by inappropriate use – e.g., using the wrong agent to treat the problem. 
Many patients will require a combination of agents to effectively control prob-
lematic bleeding. In our opinion, the ideal agent should consistently achieve rapid 
hemostasis, provide the adhesive strength necessary to minimize being washed 
away, be sufficiently strong to withstand arterial pressures, and be readily available, 
cost-effective, easy to use, easy to store at room temperature and easy to prepare 
with minimal training and little opportunity for waste. The ideal agent should also 
be biologically tolerated with minimal, if any, risk for pathologic or immunologic 
short or long-term implications. And, of course, the risk of transmission of an 
infectious agent must be zero. The management of bleeding in the setting of a 
surgical procedure, as mentioned, is associated with significantly higher operative 
times, operative costs, rates of reoperation, increased infections, and an increase 
in peri-operative morbidity and mortality. The evidence is growing that suggests 
that biological agents may play a role in reducing all of the negative clinical outcome 
parameters while also substantially reducing the amount of time in the operating 
room managing bleeding by rapidly achieve adequate and stable hemostasis [19]. A 
key component of the use of these agents is the availability of accurate and timely, 
even point of care, laboratory studies to help target specific potential defects in the 
clotting cascade with appropriate blood products and medical therapies [20]. The 
role of thromboelastography, platelet function assays, activated clotting times, and 
standard coagulation tests (prothrombin times, bleeding times, etc.) cannot be 
over-emphasized, but a comprehensive review of these tools is outside the scope of 
this text. Likewise, medical therapies, such as desmopressin (DDAVP), anti-fibri-
nolytic agents, recombinant factors, and other agents that target specific deficien-
cies in the clotting cascade and hemostatic processes must be also considered.
4. Role of biosurgical agents
The use of biological agents during surgical procedures, and especially in 
high-risk operations like cardiac surgery, can result in a significant decrease in 
transfusion rates, hospital lengths of stay, and readmission rates. Aggressive and 
timely control of surgical bleeding can have a major and significant impact on the 
overall cost of care, particularly by reducing the risks for developing postoperative 
complications. We believe that a fundamental concept is that, independent of the 
clinical impact on the patients, the costs associated with the use of these biologic 
agents can clearly be offset by the expenses saved by avoiding the costs of bleeding 
and transfusions [21].
Understanding the coagulation cascade and the body’s response to vessel and 
tissue injury is a cornerstone to using the right agent for the right clinical scenario. 
The pathway consists of the following steps:
1. Vessel injury,
2. Vasoconstriction,
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3. Platelet plug formation,
4. Fibrin clot formation, and finally
5. Fibrinolysis
Each of these steps are extremely complex with regards to the cellular response, 
the role of cytokines, chemo-attractant compounds, and the overall biochemical 
response to tissue injury and subsequent healing. Nevertheless, each step is also 
a potential site for therapeutic intervention. While the clotting cascade, includ-
ing the intrinsic, extrinsic, and common pathways, is extremely complex, a basic 
understanding of the principles is important for the effective management of 
postoperative bleeding. It is important to recognize that antiplatelet agents such 
as clopidogrel, ticagrelor, and aspirin will impact the clotting cascade at different 
points than anticoagulants such as heparin, Coumadin, and some of the newer 
generation anticoagulants (each of which also have different mechanisms, sites of 
action, and options for reversal). Understanding how all of these different drugs 
impact the hemostasis process cannot be overstated [22]. Furthermore, some drugs 
such as protamine sulfate are useful for the rapid reversal of heparin, but can 
induce a coagulopathy if not dosed properly. A significant problem in using biologi-
cal agents is the lack of education, standardization, and the spectrum of options 
clinically available. Even simple drugs such as fibrin sprays may vary in how they 
are produced in the sense that human sources behave immunologically different 
than bovine- or porcine-based products. Furthermore, defining how effective these 
agents can be is extremely difficult as a function of the variability in how to qualify 
or quantify the amount of bleeding and the response to any therapy. Even a simple 
metric like transfusion rates or need for surgical re-exploration is extremely vari-
able and subjective. The primary focus should be choosing the optimal biological 
agent for a given clinical situation and specific surgical site. One approach to better 
understanding how to manage surgical bleeding is to consider five different situa-
tions (as enumerated below) and recognizing that more than one situation can exist 
for a given clinical picture but that different therapeutic interventions might be best 
considered for a specific situation (Figure 2). These situations are:
1. Continuous oozing
2. Problematic bleeding
3. Difficult to access bleeding
4. Potential risk for re-bleeding
5. High-pressure vessel bleeding
Defining each category is also particularly important. Continuous oozing is 
defined as bleeding that will not stop with simple compression or packing and, in 
general, is annoying and time consuming. One commonly encountered example 
is suture line bleeding. Problematic bleeding reflects bleeding that is accessible 
and can be a source of problems in the perioperative period (such as requiring 
post-operative transfusions of blood and/or blood products), might be more than 
routinely encountered for a given procedure, tends to be resistant to conventional 
interventions, requires immediate attention, and most importantly, is disrup-
tive to the normal progression of an operation. Problematic bleeding is often 
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encountered in “raw surfaces” or when dealing with very friable, inflamed, or 
highly vascularized tissues. Difficult to access bleeding can occur in irregular spaces 
that might be hard to get to technically or may be difficult to visualize. Examples 
of this include underneath or behind critical structure that might be difficult (or 
unsafe) or mobilize or explore – such as behind an aortic anastomosis. This situ-
ation is further characterized by the concern that accessing the space or getting 
to the source of bleeding may result in further harm, bleeding, or tissue damage. 
The potential for re-operative bleeding is real and presents a difficult challenge, 
such as after a vessel or structure is re-pressurized, expanded, or stretched with 
appropriate use in the post-operative period. The best approach here should always 
be proactive with regards to prevention, including meticulous surgical technique 
and avoidance of tissue or suture line areas of tension. When bleeding does occur, 
the decision to re-operate should be made quickly and appropriately to define 
and address the problem. It is well-established that even a medical coagulopathy 
can improve with a simple evacuation of a hematoma, even if a definitive surgical 
source (e.g., something that needs to be technically repaired) is not encountered. 
Surgeons must remember that re-operative interventions may themselves lead to 
further postoperative bleeding that may require additional clinical escalation, such 
as through the technical disruption of an otherwise stable suture line while search-
ing for a potential source of bleeding or the accidental injury to a key structure 
in the course of re-entry into a body cavity [23]. Finally, high pressure bleeding 
is potentially deadly in that it might be arterial pressure and difficult to control if 
not immediately stopped. Even venous bleeding from large vessels or structures 
such as the right or left atrium can be immediately catastrophic if not addressed in 
a timely manner which is why protocols, guidelines, and systems must be in place 
for bedside exploration when a return to the operating room cannot happen either 
safely or quickly enough.
5. Specific agents
Once the type of bleeding is identified and consideration is given for additional 
technical interventions (e.g., more suturing or revision of surgical sites) or medical 
Figure 2. 
Clotting pathway with different sites of action of commonly used anti-platelet and anti-coagulant medications 
with potential biosurgical opportunities for management of hemostasis (see text).
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therapies (e.g., reversal of heparin with protamine), an effective next step is to 
identify an ideal biosurgical agent. Surgeons must have access to a full spectrum of 
agents and be able to choose the best option for the best scenario. It is not uncom-
mon that more than one agent is necessary for a given problem.
One commonly used type of biological agent is oxidized recombinant cellulose 
(ORC) [22]. These types of agents have a low pH which is helpful in that they not 
only induce vasoconstriction, but they can also potentially be bactericidal. They 
are often stable at room temperature and packaged in a manner that facilitates ease 
of use. They have the tendency to be reabsorbed over 1–2 weeks, which reduces the 
risk for serving as a nidus for infection or worrisome host reaction such as exces-
sive scarring or adhesions formation. In brief, the primary mechanism is that ORC 
provides a stable matrix for platelet aggregation and adhesion. These agents are 
available in a variety of different consistencies, sizes, shapes, and strengths that can 
be selected based on the clinical circumstance.
Biological gels have similar mechanisms of action in that they provide a matrix 
for platelet aggregation and adhesion [24]. These can be used along suture lines, 
boney defects, and on raw tissue surfaces. Typically, these agents are mixed with 
saline or thrombin to generate a paste that can be used in difficult to access areas. 
As discussed above, when deciding on an agent, it is important to understand that 
some of these agents are recombinant and hence immunologically inert. However, 
some are human, bovine, or porcine based and therefore have the potential short 
and long-term inflammatory immunological host responses. Allergic reactions from 
re-exposures with animal-derived products have been described and can be prob-
lematic, especially in a patient recovering from complex cardiac surgery.
Another category of biosurgical agents are the fibrin sealants. This class of 
biosurgical agents provides all the necessary components to generate a clot [25]. 
Therefore, they can be used in patients who have defects in their clotting mecha-
nisms for a variety of reasons. These agents can also be effective in patients that 
have been exposed to anticoagulant medications that inherently inhibit fibrin clot 
formation such as warfarin, heparin, and direct thrombin inhibitors. As such, by 
their mechanism of action, they are less effective in patients that have defects in 
platelet function from agents such as platelet inhibitors and aspirin. These agents 
are typically in the form of a topical spray that can be prepared in a short period of 
time and are easy to use [26].
Finally, there are a variety of non-biologic agents such as glues and adhesives 
that can be helpful in managing the full spectrum of bleeding and bleeding-related 
problems. Such agents, by definition, are not biologic (meaning they are not direct 
replacements or supplements to existing clotting factors – like thrombin, fibrin, 
and specific clotting factors, recombinant, animal-based, or human derived), and, 
hence, the mechanisms of action are based on their “glue-like” properties. They can 
induce a variety of foreign body reactions and, as they solidify, can be difficult to 
work with [27, 28].
6. Potential complications and concerns
An additional benefit of biological agents is that they, by definition and design, 
are much more biologically compatible than other potential “foreign” compounds. 
While, as discussed above, there are concerns of immune-mediated reactions 
from either a primary and repeat exposure to animal-based agents (in particular, 
bovine), such reactions are relatively uncommon – and have been predominately 
experiences in children who, as a function of their congenital heart disease, often 
require multiple complex surgical procedures [29, 30]. Interestingly, while there are 
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concerns about potential immunologic reactions, there is some evidence to suggests 
that, even in the setting of such a reaction, that the biologic hemostatic activity 
of thrombin-based medications is not always impaired [31]. Such immunological 
reactions, and potential cross-reactivities, have also been attributed to some of the 
other complications associated with other agents that impact the clotting cascade. 
The most commonly associated medication in this category is Aprotinin – a serine 
protease inhibitor that is an anti-fibrinolytic, and a platelet membrane stabilizer – 
that has since been withdrawn from commercial use in the context of concerning 
immune-mediated increased rate of peri-operative morbidity and mortality [32].
Of greater concern of some of the “glue-based” therapies is the development of 
localized cytotoxic complications. Despite routine use in complex cardiovascular 
procedures – such as aortic dissections – there are concerns about BioGlue’s© 
(CryoLife Inc. Kennesaw, GA USA), a bovine serum albumin-glutaraldehyde 
adhesive impact on tissue healing [33]. The association with the late development of 
anastomotic complications, pseudoaneurysms, vascular strictures, coronary occlu-
sions, and even embolic complications is well-described [34–36]. It is because of 
these concerns that some advocate that albumin-glutaraldehyde sealants should not 
be used in “growing tissues” and cautiously in children [37]. Nevertheless, despite 
extensive experiences and concerns regarding some of the long-term complications 
associated with these types of agents, they still remain a valuable tool in dealing 
with very difficult and surgical bleeding, especially in the setting of acute aortic 
syndromes and complex aortic surgery [38]. Some authors argue that the complica-
tions associated with BioGlue reflect more the nature of the surgery, the inherent 
pathology, and – potentially – some aspect of the surgical techniques used to man-
age catastrophic bleeding in the setting of extremely friable and disrupted tissues 
(as if often encountered with aortic dissections) [39, 40].
It cannot be emphasized enough that, as with all therapies in medicine and sur-
gery, that use must be put into the context of balancing risks and benefits. Clearly, 
bleeding, bleeding related complications, and the transfusion of blood and blood-
products introduce substantial short and long-term risks. Biologic agents to help 
attenuate such bleeding (and, hence bleeding related complications) can be very 
effective, especially in very complex and difficult surgical situations. Biosurgical 
agents can be life-saving in the setting of difficult to control surgical bleeding, 
acquired coagulopathic states, and other challenging technical scenarios. However, 
such agents are not without their own costs and potential risks. With large number 
of clinically available agents, it is imperative that clinicians be very much aware of 
the costs, mechanisms of active, and potential complications – as with any drug – of 
each. Most importantly, wide-spread use of such agents should not be a substitute 
for good surgical techniques.
7. Conclusions
Overall, reducing the need for transfusions while reducing the incidence of 
bleeding and bleeding associated complications is critical for optimizing patient 
outcomes and reducing the expenses associated with cardiovascular surgery. A mul-
tidisciplinary approach is critical in the development of an optimal blood conserva-
tion program. Recognizing preoperative patient comorbidities that might impact 
bleeding and might be modifiable is an important first step. Effectively managing 
the growing number of medications which patients are exposed to that impact the 
clotting cascade, and serve as either antiplatelets or anticoagulants is also critical 
in reducing postoperative bleeding. Avoiding or withholding these medications as 
long as possible prior to surgery is clearly beneficial, as long as no contraindications 
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t exist. Unfortunately, patients still require aggressive control of sources of bleeding 
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tions, ultimately leading to improved clinical outcomes [41]. Ongoing educational 
initiatives and experiences play a key role in a multi-disciplinary approach to the 
difficult problem of peri-operative bleeding and blood product utilization.
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